Publications by authors named "D Bar-On"
CXCR3 is a chemokine receptor with three ligands: CXCL9, CXCL10 and CXCL11. We report that in addition to attracting CXCR3+ T cells to tumor sites a key role of CXCL9 and CXCL10 is in inducing a self-feeding feedback loop that accelerates effector/cytotoxic activities of both CD4+ and CD8+ T cells while downregulating immunoregulatory protein TIM3. CXCR3KO mice displayed a markedly reduced response to anti-PD-1 and anti-CTLA-4 therapy.
View Article and Find Full Text PDFAlpha-synuclein (aSyn) aggregates in the central nervous system are the main pathological hallmark of Parkinson's disease (PD). ASyn aggregates have also been detected in many peripheral tissues, including the skin, thus providing a novel and accessible target tissue for the detection of PD pathology. Still, a well-established validated quantitative biomarker for early diagnosis of PD that also allows for tracking of disease progression remains lacking.
View Article and Find Full Text PDFObjective: Whenever a cortectomy is indicated, obviating preoperative biopsy and practicing a single-stage-laser-cordectomy (SSLC) may expedite treatment and preserve surgical planes. This may result in more superficial resections and improved vocal function. Yet, SSLC holds a risk for over-treating nonmalignant lesions.
View Article and Find Full Text PDFPurpose: To provide real-life data on azole treatment outcomes and the role of surgery in the current management of invasive fungal rhinosinusitis complicated by orbitocranial fungal infection (OCFI).
Methods: Data was collected retrospectively from a chart review from four participating centers and a systematic literature review. The study group included patients with OCFI treated with azole antifungals.
Article Synopsis
- Immunosuppression, particularly in solid organ transplant recipients and chronic lymphocytic leukemia patients, significantly increases the risk of developing aggressive cutaneous squamous cell carcinoma (cSCC) compared to immunocompetent individuals.
- This study analyzed 465 cSCC patients, comparing clinical features, treatments, and survival rates between immunosuppressed patients and controls with cSCC.
- Results showed immunosuppressed patients had higher rates of tumor recurrence, multiple tumors, and poorer overall survival rates, especially among those receiving immunomodulating treatments, with solid organ transplant recipients exhibiting the most severe outcomes.